left-arrow right-arrow pinterest facebook google_plus linkedin

ECOG-ACRIN EA5162

Status:

Suspended | Phase II

Official Title:

Phase II Study of Osimertinib in Advanced NSCLC Patients with Exon 20 Mutations in EGFR

Study Purpose:

To evaluate the best objective response rate of AZD9291 (osimertinib) among patients with EGFR exon 20 insertions.

Interventions:

  • Osimertinib 160 mg orally every day.
  • Cycle 21 days
  • CT scans for response every 6 weeks.

Key Participation Requirements:

Gender:

Male or Female

Age:

19 years and older

Diagnosis:

Stage IIIB or IV advanced non-small cell lung cancer with EGFR exon 20 insertion mutation.

Eligibility:

ECOG performance status 0 or 1.

Documentation of EGFR exon 20 insertion mutation.

Must have had at least one prior treatment for advanced and/or metastatic lung cancer-may have received more than 1 treatment.

Subjects must have disease that is measurable by CT scan.

No prior treatment with therapies targeting PDL-1 or PD1 or CTLA4.

Normal organ and bone marrow function.

Patients must sign an approved informed consent and authorization permitting release of personal health information.

Methodist Health System Trial Code:

ECOG-ACRIN EA5162

For more information, visit the U.S. National Library of Medicine clinical trial database.

To learn more about this clinical trial please contact us today!